Skip to main content
Sequana Medical N.V. logo

Sequana Medical N.V. — Investor Relations & Filings

Ticker · SEQUA ISIN · BE0974340722 LEI · 8755009AN12Y4PEOII07 BR Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2025-09-26 Share Issue/Capital Cha…
Country BE Belgium
Listing BR SEQUA

About Sequana Medical N.V.

https://www.sequanamedical.com/

Sequana Medical N.V. is a commercial-stage medical device company focused on developing treatments for drug-resistant fluid overload, a frequent complication in patients with liver disease, heart failure, and cancer. The company's primary product is the alfapump®, a fully implanted, wirelessly charged system that automatically and continuously removes ascites (fluid accumulation in the abdomen) into the bladder for natural elimination. It is the first U.S. FDA-approved active implantable medical device for treating recurrent or refractory ascites due to liver cirrhosis, designed to reduce or eliminate the need for therapeutic paracentesis. Sequana Medical is also advancing its DSR® (Direct Sodium Removal) therapy platform, a novel approach for managing fluid overload in heart failure patients.

Recent filings

Filing Released Lang Actions
2 -- Sequana Medical - RSU Shares Board Report (executed version)_Redacted.pdf
Share Issue/Capital Change Classification · 95% confidence The document is a formal 'Verslag van de Raad van Bestuur' (Report of the Board of Directors) issued by Sequana Medical NV. It details a proposed capital increase through the issuance of new shares to specific board members (restricted share units/RSUs) and justifies the cancellation of shareholder preferential rights. This type of document is a standard corporate governance and capital structure report required under Belgian company law (Wetboek van vennootschappen en verenigingen) for board-led capital transactions. It is not an annual report, earnings release, or simple announcement, but a specific management report regarding a capital change.
2025-09-26 Dutch
2 -- Sequana Medical - Loan Conversions Board Report (executed version)_Redacted.pdf
Capital/Financing Update Classification · 98% confidence The document is a formal 'Verslag van de Raad van Bestuur' (Report of the Board of Directors) issued by Sequana Medical. It details specific capital increases through debt-to-equity conversions (inbreng in natura) involving creditors Kessler and Kreos. This document is a statutory requirement under the Belgian Code of Companies and Associations (Wetboek van vennootschappen en verenigingen) to justify share issuance and capital structure changes. It is not an announcement of a report (RPA), but the report itself, and it specifically addresses capital/financing activities.
2025-09-26 Dutch
1 -- Sequana Medical - Articles of Association (NL) (26 September 2025).pdf
Audit Report / Information Classification · 95% confidence The document is a formal 'Statuten' (Articles of Association) for Sequana Medical. It outlines the company's legal structure, purpose, capital, share classes, and governance rules. In the context of corporate filings, the Articles of Association are foundational governance documents that define the company's internal rules and structure. Since there is no specific category for 'Articles of Association' in the provided list, it falls under 'Governance Information' (CGR), which covers internal rules, board structure, and governance practices. FY 2025
2025-09-26 Dutch
20250926 Sequana Medical -- Press Release loan conversion (ENG) .pdf
Share Issue/Capital Change Classification · 100% confidence The document is a formal announcement by Sequana Medical regarding a change in its share capital and the total number of outstanding shares following specific capital increase transactions (contributions in kind and cash). It explicitly references Article 15 of the Belgian Act of 2 May 2007, which governs the disclosure of major participations and capital changes. Since the document details the issuance of new shares and the resulting change in capital structure, it falls under the category of share issues and capital changes.
2025-09-26 English
20250926 Sequana Medical -- Press Release loan conversion (NL) .pdf
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory announcement from Sequana Medical NV regarding a capital increase resulting from the conversion of debt and the exercise of share units. It explicitly details the change in the number of shares and the total capital amount, citing Article 15 of the Belgian Law of 2 May 2007 regarding the disclosure of major shareholdings and capital changes. This fits the definition of a 'Share Issue/Capital Change' (SHA) announcement, as it reports on the issuance of new shares and the resulting change in capital structure.
2025-09-26 Dutch
250925 Press Release_HY 2025 and business update_25 Sept 2025 (ENG).pdf
Earnings Release Classification · 98% confidence The document is a press release titled 'Sequana Medical announces H1 2025 results and provides business update'. It contains a summary of financial highlights, business updates, and condensed financial statements for the six-month period ending 30 June 2025. While it contains financial data, it is structured as a press release (announcement) rather than a full statutory interim report. According to the 'Menu vs Meal' rule, this is the initial announcement of the results, which fits the definition of an Earnings Release (ER). H1 2025
2025-09-25 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.